LUND, Sweden, April 21, 2023 /PRNewswire/ -- Immunovia AB
(publ) today announced that the Annual Report for 2022 has been
published.
The annual report can be downloaded in pdf format and is
available on Immunovia's website:
https://investor.immunovia.com/financial-reports/.
For more information, please contact:
Karin Almqvist
Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
About Immunovia
Immunovia is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer
groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated, addressable market size of 1.8 million individuals per
year who could benefit from our test.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com
The following files are available for download:
|
https://mb.cision.com/Main/13121/3756253/2002971.pdf
|
Annual Report 2022
Immunovia
|
View original
content:https://www.prnewswire.co.uk/news-releases/immunovia-publishes-the-annual-report-for-2022-301804266.html